[Stock in Focus] Hanmi Pharm. Co., Ltd. Surges Nearly 30% in a Single Day

Shares of Hanmi Pharm. Co., Ltd. (128940) are soaring near the 540,000 KRW mark, up 29.96% from the previous trading day. The entire move occurred in a single session—a rally of nearly 30% in one day.

This move is too large to attribute to ordinary investor flows. At the time of writing, the KOSPI daily return had not yet been confirmed, but index moves of this magnitude are uncommon. The stock is outpacing the broader market. The rally appears driven by company-specific news concerning Hanmi Pharm. itself.

The strongest second-quarter results in 11 years

Hanmi Pharm.'s preliminary Q2 2026 earnings, announced July 28, show revenue of 467.2 billion KRW, a 29.3% increase year-over-year. Operating profit reached 131.1 billion KRW, representing a 116.9% increase, and net income totaled 84.1 billion KRW, up 95.5%. Both top-line and operating-profit figures mark the company's highest levels since Q4 2015—a span of 11 years.

First-half cumulative revenue stands at 860.2 billion KRW, with operating profit at 184.7 billion KRW. Commentary has emerged suggesting this may represent the company's highest revenue since its founding.

Strength in core product sales drove the operating-profit surge, reinforced by a technology-transfer agreement signed with Eli Lilly in June. The company transferred a candidate molecule, semaglutide derivative known as sonepeglutide, to Lilly. The upfront payment is $75 million, equivalent to approximately 112.9 billion KRW, which was fully recognized in Q2 earnings.

Up threefold in one year—what's driving this company

Hanmi Pharm.'s stock has climbed roughly threefold over the past year, rising approximately 200% from twelve-month lows. A significant advance compressed into a short timeframe.

Two primary catalysts have propelled the stock. First is the Eli Lilly technology-transfer deal just detailed. The total contract value reaches 1.9 trillion KRW, including milestone payments at clinical, regulatory, and commercialization stages. The company can earn an additional maximum of $1.185 billion, equivalent to approximately 1.784 trillion KRW, contingent on meeting those milestones.

The second catalyst centers on obesity treatment. Hanmi Pharm.'s proprietary GLP-1 class compound for obesity and metabolic disorders, epeglutide, represents Korea's first domestically developed drug in this category. The auto-injector formulation completed regulatory filing with the Korea Medicines and Medical Devices Safety Evaluation and Research Institute in December, and Phase 3 data at the 40-week timepoint demonstrated maximum bodyweight reduction of 30%. Domestic launch is targeted for H2 2026. As Korea's first GLP-1 obesity medication, the designation itself carries significant market attention.

Equity analysts have already raised their price targets

Hana Securities raised its price target for Hanmi Pharm. to 710,000 KRW on June 8, reflecting both the Eli Lilly technology-transfer achievement and expectations for additional licensing deals in the second half.

With today's stock climb to 540,000 KRW, the gap to the 710,000 KRW target has narrowed materially. Equity research reports reassessing the target price are now within reach.

Hanmi Pharm.'s headquarters in Songpa-gu, Seoul. Eight years ago, the company came close to recovering a market capitalization of 7 trillion KRW. If today's rally continues, that milestone may return within sight.

There are points worth noting

On August 10, Hanmi Pharm. received a warning from regulatory authorities for late notification of clinical-trial plan amendments and violations of clinical-trial quality-control standards. The action addressed first-time infractions.

The matter is not fatal. However, because drug-development velocity is central to company valuation, clinical-management issues warrant close monitoring. The specific catalyst for today's surge remains unclear at the time of writing. The move appears to reflect accumulated expectations stemming from the Eli Lilly contract, strong earnings, and anticipation surrounding the obesity drug candidate. Accurately stated: the precise trigger is not yet confirmed.

In summary, Hanmi Pharm. Co., Ltd.

By the numbers, the picture is sound: 11-year-high Q2 earnings, a 1.9 trillion KRW technology-transfer agreement, and regulatory filing for Korea's first GLP-1 obesity drug converging at once. Sell-side price targets are higher from two firms.

Yet a single-day 30% surge necessarily reflects substantial expectations already priced in. The next key milestones to watch are the expected H2 regulatory approval decision on epeglutide and anticipated additional milestone announcements from Eli Lilly. Actual delivery against these pre-priced expectations will prove decisive in validating the current valuation.

Strong earnings and multiple corporate catalysts aligning simultaneously remains an unusual configuration. Judgment should not rest on a single day's price action alone.

This article is provided for informational purposes based on public disclosures and press reports, and does not constitute an endorsement or recommendation to buy or sell any security.